<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01247623</url>
  </required_header>
  <id_info>
    <org_study_id>P03700</org_study_id>
    <nct_id>NCT01247623</nct_id>
  </id_info>
  <brief_title>Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma</brief_title>
  <official_title>Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective: Determination of safety and tolerability of GV1001 administration combined&#xD;
      with Temozolomide (based on blood samples and adverse events).&#xD;
&#xD;
      Feasibility of combining active immunisation with Temozolomide treatment. Determination of&#xD;
      immunological response after administration of GV1001 and Temozolomide as measured by&#xD;
      presence of DTH skin test reaction and specific T-cell responses.&#xD;
&#xD;
      Secondary: Evaluation of objective tumour response&#xD;
&#xD;
      The trial is an exploratory study which main objective is to estimate safety and feasibility&#xD;
      of combining active immunisation with chemotherapy. However, the trial may also indicate the&#xD;
      efficacy of the combination.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GV1001</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of malignant melanoma.&#xD;
&#xD;
          -  Previously untreated and non-resectable disease&#xD;
&#xD;
          -  Measurable or evaluable tumour.&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 75 years.&#xD;
&#xD;
          -  Performance status ECOG-WHO 0, 1 and 2 (Appendix III)&#xD;
&#xD;
          -  Written informed consent (Appendix II)&#xD;
&#xD;
          -  Adequate bone marrow liver, heart and renal function:&#xD;
&#xD;
          -  WBC count &gt;3.0 x 109/L and platelets count &gt;100 x 109/L.&#xD;
&#xD;
          -  ASAT, ALAT &lt;2 x upper normal laboratory value.&#xD;
&#xD;
          -  Serum creatinine &lt;2 x upper normal laboratory value.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with chemotherapy.&#xD;
&#xD;
          -  Clinical signs of brain metastases.&#xD;
&#xD;
          -  Severe cardiac insufficiency (NYHA III or IV) with uncontrolled and/or unstable&#xD;
             cardiac or coronary artery disease.&#xD;
&#xD;
          -  Severe active infections such as HIV or hepatitis B or Hepatitis C.&#xD;
&#xD;
          -  Medication for severe intercurrent disease which might affect immunocompetence (e.g.&#xD;
             immunosuppressants, systemic corticosteroids).&#xD;
&#xD;
          -  Pregnancy, breast-feeding or absence of adequate contraception for fertile patients.&#xD;
&#xD;
          -  Simultaneously participation in other clinical studies.&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not&#xD;
             participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <state>Postbox 4953</state>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 23, 2010</study_first_submitted>
  <study_first_submitted_qc>November 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2010</study_first_posted>
  <last_update_submitted>November 4, 2014</last_update_submitted>
  <last_update_submitted_qc>November 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <keyword>Non-resectable, advanced malignant melanoma.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

